ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither

BMJ

Volumn 316, Issue 7141, 1998, Pages 1337-

  Baigent, Colin ^a   Collins, Rory ^a   Appleby, Paul ^a   Parish, Sarah ^a   Sleight, Peter ^a   Peto, Richard ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; PLASMINOGEN ACTIVATOR; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; SURVIVAL;

ADMINISTRATION, ORAL; ADULT; AGED; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; STREPTOKINASE; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032474229     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.316.7141.1337     Document Type: Article

References (32)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
2. ISAM (Intravenous Streptokinase in Acute Myocardial Infarction) Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity and infarct size at 21 days. N Engl J Med 1986; 314: 1465-1471.
3. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
4. The AIMS (APSAC Intervention Mortality Study) Trial Study Group. Effects of intravenous APSAC on mortality after acute myocardial infarction. Preliminary report of a placebo-controlled clinical trial. Lancet 1988; 1: 545-549.
5. Wilcox RG, von der Lippe G, Olsson CJ, Jensen G, Skene AM, Hampton JR for the ASSET (Anglo-Scandinavian Study of Early Thrombolysis) Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction (ASSET). Lancet 1988; 2: 525-530.
6. P Rossi L Bolognese on behalf of Urochinasi per via Sistemica nell'Infarto Miocardico (USIM) Collaborative Group. Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction. Am J Cardiol 1991; 68: 585-592.
7. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised trial of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770.
8. EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993; 342: 767-772.
9. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759-766.
10. Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.
11. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto miocardico (GISSI). Long-term effects of intravenous thrombolysis: final report of the GISSI study. Lancet 1987; 2: 871-874.
12. Schröder R, Neuhaus K-L, Leizorovicz A, Linderer T, Tebbe U for the ISAM Study Group. A prospective placebo-controlled double-blind multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): long-term mortality and morbidity. J Am Coll Cardiol 1987; 9: 197-203.
13. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR for the Anglo-Scandinavian Study of Early Thrombolysis. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Lancet 1990; 335: 1175-1178.
14. Hillis WS, Chamberlain DA, de Bono DP, Fox KAA, Murray RG, Julian DG, et al for the AIMS Study Group. Intravenous anistreplase in acute myocardial infarction: continued reduction in mortality up to 5 years: long-term results of the AIMS study [abstract]. Eur Heart J 1992; 13(suppl): 305.
15. Simoons ML, Vos J, Tijssen JGP, Vermeer F, Verheugt FWA, Krauss XH, et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5-year follow-up of a trial conducted by the Interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol 1989; 14: 1609-1615.
16. Cerqueira MD, Maynard C, Ritchie JL, Davis KB, Kennedy JW. Long-term survival in 618 patients from the Western Washington streptokinase in myocardial infarction trials. J Am Coll Cardiol 1992; 20: 1452-1459.
17. Lenderink T, Simoons ML, Van Es G-A, Van de Werf F, Verstraete M, Arnold AER for the European Cooperative Study Group. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation 1995; 92: 1110-1116.
18. Van de Werf F. Thrombolysis for acute myocardial infarction: why is there no extra benefit after hospital discharge? Circulation 1995; 91: 2862-2864.
19. White HD. Thrombolytic therapy for patients with myocardial infarction presenting after 6 hours. Lancet 1992; 340: 221-222.
20. Rawles J. Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT). BMJ 1996; 312: 212-216.
21. White SJ, Freedman LS. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 1978; 37: 849-857.
22. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Part II: Analysis and examples. Br J Cancer 1977; 35: 1-39.
23. White HD, Cross DB, Eiliot JM, Norris RM, Yee TW. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994; 89: 61-67.
24. Lamas GA, Flaker GC, Mitchell G, Smith SC, Gersh BJ, Wun C-C, et al for the Survival and Ventricular Enlargement Investigators. Effect of infarct artery patency on prognosis after acute myocardial infarction. Circulation 1995; 92: 1101-1109.
25. Granger CB, White HD, Bates ER, Ohman EM, Califf RM. A pooled analysis of coronary artery patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol 1994; 74: 1220-1228.
26. Harrison JK, Califf RM, Woodlief LH, Kereiakes D, George BS, Stack RS, et al for the TAMI Study Group. Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. An analysis of determinants of improvement. Circulation 1993; 87: 1531-1541.
27. Volpi A, De Vita C, Franzosi MG, Geraci E, Maggioni AP, Mauri F, et al for the Ad Hoc Working Group of the Gruppo Italiano per lo Studio della Soprovvivenza nell'Infarto miocardico (GISSI)-2 data base. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis: results of the GISSI-2 data base. Circulation 1993; 88: 416-429.
28. Gurwitz JH, Goldberg RJ, Gore JM. Coronary thrombolysis for the elderly? JAMA 1991; 265: 1720-1723.
29. European Secondary Prevention Study Group. Translation of clinical trials into practice: A European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet 1996; 347: 1203-1207.
30. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, et al for the Participants in the National Registry of Myocardial Infarction. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994; 90: 2103-2114.
31. Gurwitz JH, Gore JM, Goldberg RJ, Rubison M, Chandra N, Rogers WJ for the Participants in the National Registry of Myocardial Infarction. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. Ann Intern Med 1996; 124: 283-291.
32. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.